1. A 71-year-old man with metastatic colon cancer is admitted with febrile neutropenia. Blood cultures grow Escherichia coli. Susceptibility testing shows the isolate is susceptible to piperacillin-tazobactam (MIC 8/4 mg/L) and meropenem (MIC 0.06 mg/L), with an ESBL phenotype confirmed by combination disk testing. The oncology fellow suggests piperacillin-tazobactam as definitive therapy, citing the susceptibility result and a preference for carbapenem stewardship. The infectious disease attending references a specific landmark trial when overruling this choice. Which of the following correctly identifies the trial and its findings that are directly relevant to this management decision?
A) The ALLHAT trial demonstrated that piperacillin-tazobactam and meropenem produce equivalent 30-day mortality for ESBL-producing Enterobacterales bacteremia in immunocompetent patients, but that meropenem is superior in patients with neutropenia because the lower MIC achieves a higher fT>MIC in the neutropenic AUC pharmacokinetic model; piperacillin-tazobactam is appropriate for non-neutropenic ESBL bacteremia only
B) The CREDENCE trial established that for ESBL-producing Enterobacterales bacteremia in cancer patients, carbapenem-sparing therapy with piperacillin-tazobactam plus a beta-lactamase inhibitor booster dose achieves non-inferior outcomes compared to meropenem; the attending's preference for meropenem reflects older guidelines superseded by this randomized evidence
C) The MERINO trial (a randomized controlled trial comparing piperacillin-tazobactam to meropenem for definitive treatment of ceftriaxone-resistant Enterobacterales and Pseudomonas aeruginosa bacteremia) demonstrated that piperacillin-tazobactam was inferior to meropenem, with significantly higher 30-day mortality in the piperacillin-tazobactam arm — establishing that meropenem, not piperacillin-tazobactam, is the appropriate definitive agent for ESBL-producing Enterobacterales bacteremia even when the isolate tests susceptible to piperacillin-tazobactam
D) The BLOAT trial established that piperacillin-tazobactam is non-inferior to meropenem for ESBL-producing Enterobacterales bacteremia when administered as an extended infusion over 4 hours rather than the standard 30-minute infusion; extended infusion overcomes the inoculum effect by maintaining fT>MIC above 100% throughout the dosing interval, and the attending's objection would be addressed by ordering extended-infusion piperacillin-tazobactam
E) The PATHWAY-2 trial demonstrated that for ESBL-producing bacteremia, piperacillin-tazobactam achieves superior microbiological cure compared to meropenem at 72 hours despite higher 30-day mortality in a small subgroup analysis; the trial recommended piperacillin-tazobactam for initial therapy followed by de-escalation once clinical stability is confirmed, which is the regimen the fellow is proposing
ANSWER: C
Rationale:
Option C is correct. The MERINO trial (Harris et al., JAMA 2018) was a multinational randomized controlled trial that enrolled patients with ceftriaxone-resistant Enterobacterales or P. aeruginosa bacteremia and randomized them to receive piperacillin-tazobactam 4.5 g every 6 hours versus meropenem 1 g every 8 hours as definitive therapy. The primary outcome was 30-day mortality. The trial was stopped early for harm in the piperacillin-tazobactam arm: 30-day mortality was 12.3% in the piperacillin-tazobactam group versus 3.7% in the meropenem group (p=0.90 for non-inferiority, non-inferiority not met; p=0.02 for superiority of meropenem). The excess mortality in the piperacillin-tazobactam arm was attributed to the inoculum effect — in the setting of bacteremia with high bacterial burdens, ESBL enzyme expression at these densities reduces effective piperacillin-tazobactam concentrations below the MIC despite susceptible in vitro results. These findings established meropenem as the standard of care for definitive treatment of ESBL-producing Enterobacterales bacteremia regardless of piperacillin-tazobactam in vitro susceptibility.
Option A: Option A is incorrect because ALLHAT was a landmark hypertension trial comparing antihypertensive drug classes — it has no relevance to antibiotic treatment of bacteremia, and the described pharmacokinetic model attributed to it is fabricated.
Option B: Option B is incorrect because CREDENCE was a trial of canagliflozin in patients with type 2 diabetes and chronic kidney disease — it is a nephroprotective cardiovascular outcomes trial completely unrelated to antibiotic selection for bacteremia.
Option D: Option D is incorrect because the BLOAT trial evaluated early oral step-down for Gram-negative bacteremia, not extended-infusion piperacillin-tazobactam versus meropenem; no major randomized trial has demonstrated that extended-infusion piperacillin-tazobactam achieves non-inferiority to meropenem for ESBL bacteremia, and the MERINO trial specifically used standard piperacillin-tazobactam dosing in one arm and found harm.
Option E: Option E is incorrect because PATHWAY-2 was a randomized crossover trial evaluating spironolactone as a fourth-line agent for resistant hypertension — it has no relevance to antibiotic selection for ESBL bacteremia, and the described microbiological cure finding and de-escalation recommendation are invented.
2. A 63-year-old woman with acute myeloid leukemia undergoes allogeneic stem cell transplantation and develops KPC-producing Klebsiella pneumoniae bacteremia on day 14 post-transplant. She is started on ceftazidime-avibactam, with initial clinical improvement. On day 8 of therapy, she becomes febrile again and blood cultures grow KPC-producing K. pneumoniae with a ceftazidime-avibactam MIC now 32/4 mg/L (resistant; baseline was 0.5/4 mg/L). Molecular testing of the new isolate identifies a D179Y substitution in the KPC enzyme. The fellow asks what has occurred mechanistically and what therapeutic options remain. Which of the following correctly identifies the resistance mechanism and an appropriate salvage approach?
A) The D179Y substitution in KPC increases the rate of carbapenem hydrolysis rather than reducing avibactam binding; this mutation evolved under selective pressure from the carbapenem component that trace amounts of meropenem in the ceftazidime-avibactam formulation provide; removing the meropenem component by switching to aztreonam alone would eliminate the selective pressure and allow reversion to avibactam susceptibility within 48 hours
B) The D179Y substitution converts KPC from a class A serine carbapenemase to a class B metallo-beta-lactamase by incorporating a zinc-coordinating aspartate at position 179; the new metallo-KPC is resistant to avibactam because zinc-dependent enzymes are not inhibited by diazabicyclooctane compounds; aztreonam-avibactam would similarly fail because avibactam cannot inhibit this zinc-converted enzyme, making colistin the only remaining option
C) The D179Y substitution causes constitutive overexpression of KPC through disruption of a regulatory element in the bla-KPC promoter; the increased KPC enzyme concentration titrates out avibactam molecules faster than they can be replenished by standard dosing, producing a kinetic rather than affinity-based resistance; doubling the avibactam dose while maintaining ceftazidime would restore efficacy by re-establishing inhibitory avibactam concentrations at the KPC active site
D) The D179Y substitution in KPC produces structural changes that expand the enzyme's substrate spectrum to include aztreonam; this mutation has been selected by aztreonam-avibactam rather than ceftazidime-avibactam exposure, and the timeline confirms that the patient was secretly receiving aztreonam-avibactam rather than ceftazidime-avibactam as documented; honest medication reconciliation is required before selecting alternative therapy
E) The D179Y substitution in the KPC enzyme alters the geometry of the avibactam binding pocket, reducing avibactam's ability to form a stable covalent complex with the KPC serine active site; this avibactam-resistant KPC variant retains carbapenemase activity, explaining why ceftazidime-avibactam MIC has risen while meropenem remains resistant; aztreonam-avibactam may retain activity because aztreonam escapes KPC hydrolysis through its monobactam structure while avibactam in the combination can still protect against co-produced serine enzymes, and meropenem-vaborbactam (if KPC susceptible) represents another potential option
ANSWER: E
Rationale:
Option E is correct. On-therapy ceftazidime-avibactam resistance in KPC-producing organisms through emergence of avibactam-resistant KPC variants is a well-documented clinical phenomenon, first described in 2015. The D179Y substitution (among other mutations including T243M and others) alters the geometry of the KPC active site in a way that reduces avibactam binding affinity while largely preserving carbapenemase activity — the enzyme can still hydrolyze carbapenems, but avibactam can no longer form its stable inhibitory acyl-enzyme complex. This leaves ceftazidime unprotected and explains the MIC rise from 0.5/4 to 32/4 mg/L. The bacteremia recurrence on day 8 is a characteristic on-therapy resistance emergence pattern for ceftazidime-avibactam against KPC. For salvage options: aztreonam-avibactam may retain activity because aztreonam's monobactam structure is not hydrolyzed by KPC (KPC is a carbapenemase/extended-spectrum enzyme that does not efficiently hydrolyze aztreonam), and the avibactam in the combination, while reduced in KPC-inhibitory potency against D179Y variants, can still protect aztreonam from co-produced serine beta-lactamases. Meropenem-vaborbactam uses a cyclic boronate pharmacophore (different from avibactam's diazabicyclooctane) that may retain KPC inhibitory activity against some avibactam-resistant variants depending on the specific mutation.
Option A: Option A is incorrect because the D179Y mutation does not affect carbapenem hydrolysis rate, is not selected by meropenem, and resistance reversion within 48 hours of removing selective pressure does not occur through simple drug withdrawal — KPC mutations are chromosomally stable once selected.
Option B: Option B is incorrect because the D179Y substitution does not convert KPC from a class A serine enzyme to a class B metallo-beta-lactamase; aspartate at position 179 alters avibactam binding geometry but does not introduce zinc coordination or change the catalytic mechanism; KPC D179Y remains a serine beta-lactamase.
Option C: Option C is incorrect because the D179Y mutation is a structural change in the enzyme active site, not a promoter mutation causing overexpression; increasing avibactam dose does not reliably overcome structural active site changes that reduce avibactam binding affinity, and this mechanism is not supported by clinical pharmacokinetic data.
Option D: Option D is incorrect because the D179Y mutation is selected by ceftazidime-avibactam exposure, not by aztreonam-avibactam; the temporal relationship (emergence on day 8 of documented ceftazidime-avibactam) is consistent with known on-therapy resistance emergence, and the suggestion of medication reconciliation misdirection is clinically inappropriate.
3. A 68-year-old man with end-stage renal disease on hemodialysis, type 2 diabetes, and a non-healing below-knee amputation stump wound is found to have Staphylococcus aureus bacteremia. The wound has been colonized with both MRSA and vancomycin-resistant Enterococcus faecalis for the past several months. Susceptibility testing of the S. aureus bloodstream isolate returns: oxacillin resistant, vancomycin MIC greater than 256 mg/L (resistant), teicoplanin resistant. Molecular testing confirms mecA and vanA gene acquisition. The infectious disease team identifies this as the first VRSA case at their institution. Which of the following statements correctly characterizes VRSA epidemiology and treatment, and what is the most appropriate initial antibiotic regimen?
A) This clinical scenario — chronic wound co-colonized with MRSA and VRE in a dialysis patient with diabetes — is the epidemiological archetype for VRSA emergence; vanA transfer from VRE to MRSA by conjugation produces VRSA; fewer than 20 confirmed VRSA cases have been reported in the United States since 2002; treatment options include linezolid and daptomycin (both typically retain activity), and the regimen should be selected with infectious disease consultation given the extreme rarity and complexity of this pathogen
B) VRSA emerges exclusively through horizontal gene transfer from environmental Bacillus species carrying vanA in soil-contaminated chronic wounds; hemodialysis patients are at elevated risk because dialysis water systems harbor vanA-containing Bacillus spores that colonize vascular access wounds; treatment requires a combination of linezolid plus rifampicin, as daptomycin is inactive against VRSA due to the vanA-mediated membrane charge modification that simultaneously blocks both vancomycin and daptomycin binding
C) VRSA is clinically defined as any S. aureus with vancomycin MIC greater than 8 mg/L regardless of mechanism; the prevalence of VRSA in US hospitals is approximately 2-3% of all S. aureus bacteremia isolates based on the most recent CDC surveillance data; empiric coverage for VRSA should be included in all initial antibiotic regimens for dialysis-associated S. aureus bacteremia given this prevalence
D) VRSA resistance to vancomycin and teicoplanin simultaneously confirms the vanA genotype because vanB confers resistance only to vancomycin and not teicoplanin; this dual glycopeptide resistance also predicts cross-resistance to daptomycin through a shared lipid II targeting mechanism; linezolid is therefore the only appropriate monotherapy agent, and combination regimens increase the risk of linezolid-associated thrombocytopenia without additional benefit
E) The vanA gene in VRSA encodes a modified PBP2a enzyme with reduced affinity for both vancomycin and all beta-lactams; ceftaroline retains partial activity against VRSA because its allosteric PBP2a engagement mechanism is not blocked by D-Ala-D-Lac substitution, and combination ceftaroline plus fosfomycin has demonstrated clinical cure in all 6 published VRSA bacteremia cases; this combination is preferred over linezolid and daptomycin based on emerging evidence
ANSWER: A
Rationale:
Option A is correct. The clinical scenario described — a hemodialysis patient with diabetes, co-colonization of a chronic wound with both MRSA and VRE, and eventual isolation of S. aureus with vancomycin MIC >256 mg/L and confirmed mecA plus vanA — is the canonical epidemiological presentation of VRSA. All confirmed VRSA cases in the United States have involved patients with co-colonization by both MRSA and VRE in a shared anatomical site (most often chronic wounds, diabetic foot ulcers, or dialysis access sites) that provides the cell-to-cell proximity needed for conjugative transfer of Tn1546 (carrying vanA) from the VRE donor to the MRSA recipient. Fewer than 20 confirmed VRSA cases have been reported in the United States since the first case in Michigan in 2002, making this an extremely rare but pharmacologically and epidemiologically important pathogen. Most reported VRSA isolates retain susceptibility to linezolid, daptomycin, and trimethoprim-sulfamethoxazole (TMP-SMX); these are the primary treatment options, and infectious disease consultation is essential given the rarity of clinical experience.
Option B: Option B is incorrect because VRSA does not originate from environmental Bacillus species; it arises through conjugative transfer of vanA from VRE to MRSA — the VRE donor is always the source, not environmental bacteria; additionally, daptomycin is not inactive against VRSA through the mechanism described — vanA modifies peptidoglycan precursors, not membrane phospholipid charge in the way that would block daptomycin's membrane-depolarizing activity.
Option C: Option C is incorrect because VRSA is not defined by MIC alone without genotypic confirmation, and the prevalence of 2-3% of all S. aureus bacteremia is wildly inaccurate — VRSA is extraordinarily rare with fewer than 20 US cases confirmed in over 20 years; empiric VRSA coverage in all dialysis S. aureus bacteremia would represent a profound stewardship failure.
Option D: Option D is incorrect because daptomycin's mechanism of action (membrane depolarization through calcium-dependent membrane insertion) is not related to the vanA D-Ala-D-Lac modification — vanA does not confer daptomycin resistance through a shared lipid II mechanism, and most VRSA isolates tested to date retain daptomycin susceptibility.
Option E: Option E is incorrect because vanA encodes enzymes for peptidoglycan precursor modification, not a modified PBP2a; MRSA PBP2a is encoded by mecA and is a separate resistance element from vanA; and ceftaroline-fosfomycin is not established as the treatment of choice for VRSA based on published cases.
4. A 74-year-old man with stage 3B chronic kidney disease (CKD) and bilateral bronchiectasis develops a pan-resistant Pseudomonas aeruginosa pneumonia with only colistin and polymyxin B susceptibility. The nephrology team is concerned about further acute kidney injury. The infectious disease fellow notes that polymyxin B and colistin (polymyxin E) have important pharmacokinetic differences that are clinically relevant to this patient. Which of the following correctly identifies the key pharmacokinetic distinction and explains why it influences nephrotoxicity risk?
A) Polymyxin B is eliminated primarily through biliary excretion with less than 5% renal elimination, while colistin undergoes extensive hepatic glucuronidation that produces nephrotoxic metabolites concentrated in renal tubular cells; polymyxin B is preferred in renal impairment because biliary elimination bypasses renal tubular exposure entirely and the non-nephrotoxic parent compound is the active species
B) Colistin has superior lung tissue penetration compared to polymyxin B because colistin's sulfate ester group enables active transport through the pulmonary epithelial sodium channel (ENaC); polymyxin B accumulates in renal proximal tubular cells but not in lung parenchyma; for pulmonary infections, colistin is preferred regardless of renal function because polymyxin B does not achieve bactericidal concentrations in bronchoalveolar lavage fluid
C) Polymyxin B and colistin have identical nephrotoxicity risk because both are direct tubular toxins through the same mechanism of cationic membrane disruption in proximal tubular cells; the choice between them for a patient with CKD should be based exclusively on organism susceptibility MIC differences, as any pharmacokinetic distinction between the two compounds is clinically negligible at therapeutic doses
D) Colistin is administered as the inactive prodrug colistimethate sodium (CMS), which undergoes partial renal elimination before conversion to active colistin; in patients with renal impairment, CMS accumulates and is cleared by the kidney before converting to active drug, resulting in both reduced efficacy due to lower active colistin concentrations and increased renal tubular exposure to the prodrug; polymyxin B is administered as the active compound and does not undergo renal prodrug conversion, giving it a pharmacokinetic advantage in this patient with CKD
E) Polymyxin B requires dose adjustment for renal impairment because it is filtered at the glomerulus and reabsorbed in the proximal tubule; in patients with CKD, reduced glomerular filtration causes polymyxin B to accumulate to nephrotoxic concentrations in tubular cells; colistin by contrast is not filtered and does not accumulate in renal tubular cells, making colistin the preferred polymyxin for patients with pre-existing renal impairment
ANSWER: D
Rationale:
Option D is correct. Colistin (polymyxin E) is not administered directly; the formulation used clinically is colistimethate sodium (CMS), an inactive prodrug in which the amino groups are sulfomethylated. CMS itself has no antibacterial activity and must be hydrolyzed to active colistin to exert its membrane-disrupting bactericidal effect. A critical pharmacokinetic consequence is that CMS undergoes significant renal elimination: it is filtered at the glomerulus and partially excreted in urine before completing conversion to colistin. In patients with renal impairment, CMS elimination is reduced, causing prodrug accumulation; more CMS reaches the kidney tubules, where slow conversion occurs with prolonged tubular exposure to the prodrug. Additionally, active colistin generated systemically is nephrotoxic through direct tubular membrane disruption. The combination of prodrug renal accumulation and active drug tubular toxicity makes colistin nephrotoxicity a particularly complex problem in CKD. Polymyxin B, by contrast, is administered as the active compound with no prodrug step; its pharmacokinetics are not renal-dependent in the same way, and dose adjustment is based on non-renal parameters. For patients with renal impairment where additional acute kidney injury is a concern, polymyxin B offers a pharmacokinetic rationale for preference over colistin.
Option A: Option A is incorrect because polymyxin B is not primarily eliminated through biliary excretion; it undergoes non-renal elimination through tissue redistribution but not through a biliary pathway that categorically bypasses renal exposure — the primary distinction from colistin is the prodrug pharmacokinetic difference, not a biliary elimination advantage.
Option B: Option B is incorrect because colistin's pulmonary penetration is actually poor when administered intravenously (a well-recognized limitation), and ENaC-mediated active transport is not an established mechanism for colistin pulmonary distribution; the comparison described inverts the known lung penetration characteristics of these agents.
Option C: Option C is incorrect because while both compounds are cationic tubular toxins, their nephrotoxicity profiles are not identical — the prodrug pharmacokinetics of CMS/colistin introduce a clinically meaningful distinction in patients with renal impairment that makes polymyxin B pharmacokinetically preferable in this patient.
Option E: Option E is incorrect because the description inverts the pharmacokinetic realities: it is colistin (as CMS) that undergoes significant renal elimination and dose adjustment in CKD, while polymyxin B pharmacokinetics are less renal-dependent; the assertion that polymyxin B requires dose adjustment for renal impairment while colistin does not contradicts established pharmacokinetic data.
5. An infection control practitioner identifies a cluster of 5 KPC-producing Klebsiella pneumoniae bloodstream infections over 3 weeks in a medical ICU. Whole-genome sequencing of all 5 isolates confirms they belong to sequence type 258 (ST258) and carry KPC-2 on IncFII plasmids. No epidemiological link between patients is identified by traditional contact tracing. The hospital epidemiologist explains why ST258 is particularly successful at nosocomial spread and why traditional contact tracing alone may be insufficient to control this outbreak. Which of the following correctly characterizes the epidemiological features of ST258 that account for its global dominance in healthcare-associated KPC outbreaks?
A) ST258 achieves healthcare dominance because it produces a unique exopolysaccharide capsule (KL107 serotype) that resists phagocytosis more effectively than all other K. pneumoniae sequence types; this hypervirulence phenotype enables ST258 to cause symptomatic infection in every colonized patient, making clinical detection straightforward and contact tracing reliable; the absence of an epidemiological link in this cluster indicates a common environmental source such as contaminated IV solutions
B) ST258 combines several fitness attributes that facilitate silent healthcare transmission: it colonizes the human gut asymptomatically at high density without causing diarrhea or other detectable symptoms, enabling prolonged silent carriage and patient-to-patient spread through transiently contaminated healthcare worker hands and environmental surfaces without ever producing clinically apparent illness in the colonizing host; traditional contact tracing misses silent gut carriers who are the primary transmission reservoir
C) ST258's global success reflects its unique ability to produce KPC constitutively at very high levels through a clade-specific promoter mutation that eliminates all regulatory control of bla-KPC transcription; this constitutive hyperexpression produces carbapenem MICs above 256 mg/L in all ST258 isolates, which is why standard carbapenem dosing reliably fails even in patients with normal renal function; the cluster represents treatment failure rather than nosocomial transmission
D) ST258 is the dominant KPC-producing lineage in the United States exclusively because it was the first K. pneumoniae strain to acquire KPC-2 in New York City hospitals in 2001; its current prevalence reflects founder effect rather than any specific fitness advantage; molecular epidemiology tools can replace traditional contact tracing entirely for ST258 because whole-genome sequencing can identify the index case retrospectively with single-nucleotide precision
E) ST258 achieves dominance through constitutive overexpression of KPC combined with OprD loss and MexAB-OprM upregulation; this triple resistance mechanism allows ST258 to persist on inanimate surfaces for up to 6 months at room temperature; environmental decontamination with standard quaternary ammonium compounds is ineffective because the outer membrane of ST258 has evolved specific resistance to cationic biocides through PhoPQ-mediated lipid A modification
ANSWER: B
Rationale:
Option B is correct. ST258 K. pneumoniae is the dominant KPC-producing lineage responsible for the majority of KPC outbreaks in North America and Europe, and its success in healthcare settings reflects multiple fitness attributes rather than any single factor. A defining feature is its capacity for prolonged asymptomatic gut colonization — ST258 colonizes the gastrointestinal tract of hospitalized patients without producing diarrhea, detectable symptoms, or obvious clinical illness. This silent gut carriage is the primary transmission reservoir: colonized patients shed organisms in stool, which contaminate healthcare worker hands, environmental surfaces, and shared equipment; the organisms then spread to new patients who also become asymptomatic gut carriers. Standard clinical surveillance based on symptomatic presentation misses these carriers entirely, and even traditional contact tracing based on room proximity or procedure sharing may fail to identify transmission chains because the colonizing patients were never ill from the organism. Active surveillance cultures — rectal swabs of high-risk patients — are required to detect this silent colonization reservoir, which is why the absence of an apparent epidemiological link in this cluster is expected rather than surprising.
Option A: Option A is incorrect because ST258 is not characterized by a KL107 hypervirulence capsule that causes symptomatic infection in every colonized patient — in fact, the opposite is true; ST258 is typically a lower-virulence pathogen that causes predominantly healthcare-associated infections in immunocompromised or critically ill hosts and is notable for asymptomatic gut colonization, not universal symptomatic infection.
Option C: Option C is incorrect because ST258 does not carry a constitutive hyperexpressing KPC promoter with MICs above 256 mg/L in all isolates; KPC expression levels and resulting carbapenem MICs vary considerably across isolates, and the cluster represents transmission of a resistant pathogen, not treatment failure of a uniformly untreatable organism.
Option D: Option D is incorrect because founder effect alone does not account for ST258's sustained global dominance over more than two decades; its fitness attributes — including gut colonization capacity, plasmid transferability, and environmental persistence — provide genuine competitive advantages, not just historical priority; and whole-genome sequencing complements rather than replaces contact tracing in outbreak investigation.
Option E: Option E is incorrect because MexAB-OprM is a P. aeruginosa efflux system, not a K. pneumoniae system; ST258 K. pneumoniae does not harbor MexAB-OprM, and surface persistence of 6 months and quaternary ammonium resistance are not established features of ST258 distinguishing it from other K. pneumoniae lineages.
6. A 57-year-old woman with liver failure and VRE Enterococcus faecium bacteremia is treated with daptomycin 8 mg/kg/day. Initial blood cultures clear on day 3. On day 10 she becomes febrile again and repeat blood cultures grow VRE E. faecium with a daptomycin MIC now 6 mg/L (non-susceptible; baseline MIC was 1 mg/L). The isolate remains susceptible to linezolid. The fellow asks why daptomycin resistance emerged and whether this is expected in enterococcal infections treated with prolonged daptomycin. Which of the following correctly explains the mechanism of on-therapy daptomycin non-susceptibility in enterococci and guides the appropriate management change?
A) Daptomycin non-susceptibility in enterococci emerges through acquisition of the vanA gene cluster from co-colonizing VRE strains; vanA-encoded D-Ala-D-Lac modification of the peptidoglycan precursor sterically blocks daptomycin's calcium-dependent membrane insertion by altering the surface topology of the cell membrane; because the patient is already VRE, this mechanism produces a progressive MIC increase during therapy rather than a sudden resistance emergence
B) Daptomycin non-susceptibility develops because E. faecium constitutively produces a daptomycin-inactivating phosphodiesterase encoded on the IncFII plasmid carrying vanA; this enzyme cleaves the fatty acid tail of daptomycin, abolishing its membrane-inserting activity; the emergence of non-susceptibility on day 10 reflects expansion of the plasmid-carrying subpopulation under daptomycin selection pressure, and switching to any lipopeptide antibiotic will fail because the phosphodiesterase has broad lipopeptide substrate specificity
C) Daptomycin non-susceptibility in enterococci arises through chromosomal mutations — particularly in the liaFSR regulatory system and cardiolipin synthase (cls) genes — that progressively alter the phospholipid composition and reduce the net negative surface charge of the cell membrane, impairing daptomycin's calcium-dependent membrane insertion and depolarization; this is a recognized complication of prolonged daptomycin therapy for enterococcal bacteremia and deep-seated infections, and the appropriate change is to linezolid or consultation regarding newer lipoglycopeptides
D) Daptomycin non-susceptibility on day 10 reflects tolerance rather than resistance; the organism has entered a stationary-phase persister state induced by sustained daptomycin exposure in which non-replicating bacteria cannot be killed by any membrane-active agent; increasing the daptomycin dose to 12 mg/kg/day and extending the infusion to 4 hours will overcome tolerance by achieving membrane depolarization kinetics that kill persister cells, and no agent change is required
E) Daptomycin non-susceptibility emerged because the liver failure patient's reduced hepatic conversion of daptomycin precursor to its active calcium-chelated form produced subtherapeutic active-drug concentrations throughout therapy; the rising MIC reflects a pharmacokinetic rather than microbiological event, and correcting the active-drug deficit by switching to IV colistin — which does not require hepatic activation — will restore bactericidal activity against this isolate
ANSWER: C
Rationale:
Option C is correct. Daptomycin non-susceptibility emerging during enterococcal therapy is a well-characterized clinical phenomenon driven by chromosomal adaptive mutations rather than horizontal gene transfer. The primary mechanism involves mutations in the liaFSR (lipid II-interacting antibiotic sensing) two-component regulatory system and in cardiolipin synthase (cls) genes. These mutations progressively alter the phospholipid composition of the enterococcal cell membrane — specifically increasing the proportion of diglucosyl-diacylglycerol and reducing the net negative surface charge — which impairs the calcium-dependent membrane insertion and depolarization that constitute daptomycin's mechanism of action. This is well-documented in E. faecalis and E. faecium during prolonged treatment of bacteremia and deep-seated infections. Switching to linezolid, which acts on the 50S ribosomal subunit through an entirely different mechanism, is the appropriate change when daptomycin non-susceptibility emerges and linezolid susceptibility is confirmed.
Option A: Option A is incorrect because daptomycin non-susceptibility in enterococci is mediated by chromosomal mutations in membrane lipid regulatory genes, not by vanA acquisition; the patient's pre-existing VRE status does not cause daptomycin non-susceptibility — these resistance pathways are mechanistically unrelated.
Option B: Option B is incorrect because no daptomycin-inactivating phosphodiesterase exists on enterococcal plasmids; daptomycin resistance in enterococci is exclusively mediated by membrane-adaptive chromosomal mutations, not enzymatic drug degradation.
Option D: Option D is incorrect because the rising MIC from 1 to 6 mg/L represents genuine microbiological resistance, not persister-state tolerance; persister cells do not produce higher MIC values on standard susceptibility testing, and dose escalation does not overcome the structural membrane changes responsible for liaFSR-mediated resistance.
Option E: Option E is incorrect because daptomycin does not require hepatic conversion to an active form; it is administered as the active cyclic lipopeptide, liver failure does not reduce daptomycin activity through a prodrug mechanism, and colistin acts on Gram-negative outer membrane lipid A and has no activity against Gram-positive enterococci.
7. A 52-year-old man with recurrent pancreatitis and a pancreatic abscess develops Klebsiella pneumoniae bacteremia. Molecular resistance testing confirms the isolate produces both NDM-1 (a metallo-beta-lactamase) and OXA-48 (a class D serine carbapenemase). The susceptibility panel shows resistance to all carbapenems, ceftazidime-avibactam, ceftolozane-tazobactam, and aztreonam alone; susceptibility is reported only for aztreonam-avibactam (MIC 0.5/4 mg/L) and colistin (MIC 1 mg/L). The fellow asks why ceftazidime-avibactam fails against an isolate producing OXA-48 (a serine enzyme that avibactam should inhibit) and why aztreonam-avibactam retains activity. Which of the following is the most accurate mechanistic explanation?
A) Ceftazidime-avibactam fails because avibactam, while successfully inhibiting OXA-48, cannot inhibit NDM; NDM rapidly hydrolyzes ceftazidime before it can reach PBPs, and avibactam provides no protection against MBL hydrolysis; aztreonam-avibactam retains activity because aztreonam's monobactam ring structure resists NDM hydrolysis, while avibactam protects aztreonam from OXA-48 hydrolysis — the combination is uniquely suited to NDM + OXA-48 co-producers precisely because each drug component addresses the resistance mechanism that the other cannot
B) Ceftazidime-avibactam fails against OXA-48 because the OXA-48 active site geometry prevents avibactam acylation in the presence of NDM; the co-expression of NDM creates a steric interaction across the periplasm that distorts OXA-48 into an avibactam-inaccessible conformation; aztreonam-avibactam overcomes this because aztreonam activates a conformational change in OXA-48 that restores avibactam binding — a priming mechanism specific to monobactam-containing combinations
C) Aztreonam alone is reported resistant because the isolate produces ESBLs in addition to NDM and OXA-48; aztreonam-avibactam appears active only because the avibactam component inhibits the ESBLs while NDM continues to hydrolyze aztreonam at a slower rate; the susceptibility result is likely a false susceptible that will fail clinically because no combination can protect aztreonam from NDM hydrolysis at in vivo bacterial densities
D) Ceftazidime-avibactam fails because ceftazidime independently induces NDM gene expression through a beta-lactam sensing regulatory system on the NDM plasmid; this induction produces a burst of NDM enzyme that overwhelms avibactam capacity within 30 minutes of drug administration; aztreonam-avibactam succeeds because aztreonam is the specific ligand for the NDM repressor protein, binding it and preventing NDM induction during therapy
E) Both ceftazidime-avibactam and aztreonam-avibactam fail against NDM because avibactam is rapidly inactivated by NDM's zinc ions under the reducing conditions of the periplasm; the reported aztreonam-avibactam susceptibility reflects testing at atmospheric oxygen conditions that do not replicate the anaerobic periplasm of Klebsiella pneumoniae; the actual active agent in aztreonam-avibactam is aztreonam alone, which achieves activity through a zinc-sequestering mechanism that temporarily depletes NDM's cofactors
ANSWER: A
Rationale:
Option A is correct. This question requires understanding the complementary resistance mechanisms operating in this co-producer and how aztreonam-avibactam addresses both simultaneously. The isolate produces two distinct beta-lactamases: NDM-1, a class B metallo-beta-lactamase that is not inhibited by avibactam (because avibactam targets serine residues and NDM uses zinc); and OXA-48, a class D serine carbapenemase that is inhibited by avibactam. Ceftazidime-avibactam fails because even though avibactam successfully inhibits OXA-48, it cannot inhibit NDM — and NDM rapidly hydrolyzes ceftazidime, rendering the combination ineffective. The key insight is that avibactam handles only the serine beta-lactamase half of the resistance; it cannot address the MBL half. Aztreonam-avibactam addresses both: aztreonam is a monobactam that is structurally resistant to hydrolysis by MBLs including NDM (MBLs evolved to hydrolyze bicyclic ring systems, not the monocyclic aztreonam ring), so aztreonam escapes NDM. Avibactam then protects aztreonam from OXA-48 (and any co-produced ESBLs) by inhibiting these serine enzymes. The combination is uniquely suited to organisms with this dual resistance profile. The aztreonam monotherapy resistance reported on the panel confirms that co-produced serine enzymes (OXA-48 and/or ESBLs) would destroy aztreonam without avibactam protection — exactly what the combination resolves.
Option B: Option B is incorrect because there is no established periplasmic steric interaction between NDM and OXA-48 that creates an avibactam-inaccessible OXA-48 conformation; ceftazidime-avibactam failure against OXA-48 co-producers is due to NDM hydrolysis of ceftazidime, not altered OXA-48 geometry.
Option C: Option C is incorrect because aztreonam's monobactam structure genuinely resists NDM hydrolysis — this is a well-validated structural characteristic, not a rate-dependent phenomenon; the susceptibility result is clinically actionable, and aztreonam-avibactam is not expected to fail from NDM-mediated aztreonam hydrolysis.
Option D: Option D is incorrect because ceftazidime does not induce NDM gene expression through a beta-lactam sensing system, and aztreonam is not an NDM repressor ligand; NDM gene regulation is plasmid-based and the mechanism described is invented.
Option E: Option E is incorrect because avibactam is not inactivated by zinc ions and the periplasm of K. pneumoniae is not anaerobic in a way that would inactivate avibactam; aztreonam's activity against NDM-producers is through structural MBL resistance, not zinc sequestration.
8. A 59-year-old woman with type 2 diabetes is hospitalized with Klebsiella pneumoniae bacteremia from a urinary source. The isolate is susceptible to ciprofloxacin (MIC 0.06 mg/L), ceftriaxone, and ertapenem; no ESBL or carbapenemase is detected. She receives ceftriaxone IV for 4 days and by day 5 is afebrile, hemodynamically stable, tolerating oral diet, and her repeat blood cultures at 48 hours have been negative. The hospitalist proposes oral step-down to ciprofloxacin to facilitate discharge. The infectious disease consultant supports the step-down but asks the team to confirm criteria are met. Which of the following best characterizes the evidence-based criteria for safe early oral step-down in this patient and the limitations of this approach?
A) Early oral step-down is appropriate only for E. coli bacteremia, not K. pneumoniae, because K. pneumoniae bacteremia carries a 3-fold higher risk of occult metastatic seeding to joints and vertebral bodies than E. coli; the BLOAT trial excluded K. pneumoniae isolates, and extrapolation to this species requires caution until species-specific data are published
B) Early oral step-down at day 5 is premature for any Gram-negative bacteremia with a urinary source because the urinary focus itself continues to seed the bloodstream even when blood cultures are negative at 48 hours; a minimum of 7 days of IV therapy is required to eradicate the urinary reservoir before oral step-down is safe, regardless of clinical stability or susceptibility profile
C) Oral step-down should use trimethoprim-sulfamethoxazole (TMP-SMX) rather than ciprofloxacin even when ciprofloxacin susceptibility is confirmed, because TMP-SMX achieves higher bactericidal concentrations in the urinary tract and kidneys compared to fluoroquinolones, and fluoroquinolone oral step-down for K. pneumoniae bacteremia is associated with a 40% relapse rate within 30 days based on retrospective cohort data
D) The criteria for early oral step-down include source control confirmed, clinical improvement, ability to absorb oral medications, and susceptibility to an oral agent with high bioavailability; K. pneumoniae bacteremia without ESBL meets these criteria in this patient, but ciprofloxacin should not be used as step-down because fluoroquinolone exposure in K. pneumoniae selectively induces the MarA efflux regulatory system, conferring in vivo resistance to ciprofloxacin within 48 hours despite a susceptible in vitro MIC
E) The criteria for early oral step-down are met in this patient: clinical stability, tolerating oral intake, negative follow-up blood cultures, susceptible isolate, and availability of a high-bioavailability oral agent (ciprofloxacin bioavailability approximately 70-80%); multiple prospective trials including the BLOAT trial have demonstrated non-inferiority of early oral step-down compared to continued IV therapy in stable Gram-negative bacteremia — oral ciprofloxacin step-down is appropriate, with a limitation that this approach applies only when the oral agent achieves serum concentrations reliably above the MIC and source control has been achieved
ANSWER: E
Rationale:
Option E is correct. The evidence base for early oral step-down in Gram-negative bacteremia has strengthened considerably with prospective trial data. The BLOAT trial (Bacteremia Low-risk Oral Antibiotic Treatment, Punjabi et al.) and complementary studies demonstrated that in patients with Gram-negative bacteremia who are clinically stable, tolerating oral intake, have negative follow-up blood cultures, and have isolates susceptible to a high-bioavailability oral agent, early oral step-down produces outcomes non-inferior to continued IV therapy. The criteria validated by these trials are: clinical improvement (afebrile, hemodynamically stable), ability to absorb oral medications (no malabsorption, tolerating oral diet), confirmed blood culture clearance, susceptibility to the oral agent, and an oral agent with high bioavailability — ciprofloxacin meets this criterion at approximately 70-80% bioavailability, achieving serum concentrations well above the MIC of 0.06 mg/L. The important limitation is that this approach applies only when all criteria are met and source control has been addressed; it does not apply to complicated infections (endocarditis, osteomyelitis, prosthetic material infection) or when the oral agent's bioavailability is uncertain (e.g., in patients with bowel edema from sepsis).
Option A: Option A is incorrect because the BLOAT trial did not specifically exclude K. pneumoniae, and there is no established 3-fold higher metastatic seeding risk for K. pneumoniae versus E. coli bacteremia that would preclude oral step-down by species.
Option B: Option B is incorrect because the urinary source in this patient represents a cleared focus — negative 48-hour blood cultures confirm clearance of bacteremia, and urinary tract bacteremia does not require a minimum of 7 days of IV therapy by evidence-based guidelines when clinical criteria for step-down are met.
Option C: Option C is incorrect because the 40% ciprofloxacin relapse rate cited is not supported by IDSA-endorsed data, and TMP-SMX is not preferred over ciprofloxacin for step-down of susceptible K. pneumoniae bacteremia based on comparative bioavailability or guideline recommendation.
Option D: Option D is incorrect because ciprofloxacin does not clinically induce MarA-mediated in vivo resistance within 48 hours at bactericidal concentrations — this described mechanism is pharmacologically overstated; MarA regulatory induction contributes to basal efflux but does not reliably convert a susceptible isolate to clinical resistance during a short therapeutic course at concentrations well above the MIC.
9. A 67-year-old man with a recent kidney transplant develops a pan-resistant Acinetobacter baumannii pneumonia. The isolate produces OXA-23 carbapenemase and is resistant to all carbapenems, ceftazidime-avibactam, aztreonam-avibactam, and colistin. The only agent showing in vitro susceptibility is cefiderocol (MIC 0.5 mg/L). The fellow asks how cefiderocol achieves activity against an organism resistant to all other available agents and what patient populations benefit most from its use. Which of the following correctly characterizes cefiderocol's mechanism and clinical positioning?
A) Cefiderocol achieves pan-resistant activity by targeting a novel bacterial enzyme, LpxC (UDP-3-O-acyl-N-acetylglucosamine deacylase), that is essential for lipid A biosynthesis and is absent from mammalian cells; because LpxC is present in all Gram-negative bacteria regardless of beta-lactamase content, cefiderocol is active against organisms with any combination of resistance mechanisms and does not require entry through the outer membrane
B) Cefiderocol is a siderophore cephalosporin that conjugates a catechol moiety to the cephalosporin scaffold; bacteria actively transport cefiderocol into the periplasm via iron-scavenging TonB-dependent siderophore uptake systems, achieving periplasmic concentrations that overcome both beta-lactamase production and porin loss; once internalized, cefiderocol inhibits PBPs in the standard cephalosporin fashion, and its activity against MBL-producing and pan-resistant organisms reflects entry bypass of conventional outer membrane permeability barriers
C) Cefiderocol achieves pan-resistant activity by directly chelating the zinc ions in the active sites of metallo-beta-lactamases including NDM and VIM; the catechol siderophore component binds both zinc cofactors simultaneously, producing irreversible enzyme inactivation; cefiderocol is therefore primarily an MBL inhibitor that incidentally also inhibits PBPs, and its activity against carbapenemase-negative organisms reflects off-target PBP binding at high concentrations
D) Cefiderocol bypasses all resistance mechanisms because it targets PBP4, a transpeptidase isoform unique to Acinetobacter baumannii that is constitutively expressed at 50-fold higher density than PBP1-3; because PBP4 is not the target of any other approved antibiotic class, no existing resistance mechanism cross-protects against cefiderocol, and its activity is not affected by any beta-lactamase, efflux pump, or porin mutation
E) Cefiderocol's activity reflects its ability to form a stable non-covalent complex with the lipopolysaccharide of A. baumannii outer membrane that physically sequesters the organism's surface charge, preventing colistin-type membrane disruption while simultaneously blocking OXA-23 enzyme activity through allosteric binding; this dual mechanism makes cefiderocol uniquely active against organisms with concurrent colistin and carbapenem resistance
ANSWER: B
Rationale:
Option B is correct. Cefiderocol is a siderophore cephalosporin — a structural class that conjugates a catechol siderophore moiety to a cephalosporin scaffold, exploiting the bacterial iron acquisition system to achieve periplasmic delivery. Iron is an essential nutrient for bacterial growth, and Gram-negative bacteria express TonB-dependent outer membrane receptors that actively transport iron-siderophore complexes across the outer membrane. Cefiderocol's catechol group chelates iron and is then recognized and transported by these siderophore uptake systems, carrying the attached cephalosporin scaffold into the periplasm via active transport rather than passive porin diffusion. This "Trojan horse" delivery mechanism achieves intracellular concentrations that are substantially higher than those achievable through conventional outer membrane diffusion, overcoming two of the most important Gram-negative resistance mechanisms: porin loss (since the drug bypasses porins entirely) and efflux (since the concentration achieved overcomes efflux-driven reduction). Once in the periplasm, cefiderocol inhibits PBPs in the standard cephalosporin fashion. Cefiderocol's stability against MBLs reflects its cephalosporin ring structure with specific stabilizing substituents, making it resistant to hydrolysis by a broad range of beta-lactamases including metallo-beta-lactamases. This combination of properties makes it specifically useful for organisms with multiple convergent resistance mechanisms including pan-resistant A. baumannii, P. aeruginosa, and MBL-producing Enterobacterales.
Option A: Option A is incorrect because cefiderocol inhibits PBPs (penicillin-binding proteins) rather than LpxC; LpxC inhibitors are a distinct investigational drug class, and cefiderocol's mechanism is standard PBP inhibition delivered through a novel siderophore entry pathway.
Option C: Option C is incorrect because cefiderocol does not chelate zinc and does not inhibit metallo-beta-lactamases; the catechol moiety chelates iron (ferric iron Fe³⁺) for siderophore transport, not the zinc ions in MBL active sites; cefiderocol's resistance to MBL hydrolysis is structural, not through enzyme inhibition.
Option D: Option D is incorrect because cefiderocol does not target a PBP4 isoform unique to A. baumannii; it inhibits the same PBP1b, PBP2, and PBP3 targets as other cephalosporins, and its activity advantage comes from the delivery mechanism, not from targeting a novel isoform.
Option E: Option E is incorrect because cefiderocol does not sequester LPS charge or allosterically inhibit OXA-23; it is a PBP inhibitor delivered through siderophore transport, and its mechanism has no relationship to colistin-type membrane disruption or OXA-23 enzyme allosteric binding.
10. A 44-year-old woman with recurrent UTIs and a sulfa allergy presents with dysuria and urinary frequency. Urine culture grows ESBL-producing E. coli resistant to ampicillin, ciprofloxacin, ceftriaxone, and TMP-SMX, but susceptible to fosfomycin (MIC 8 mg/L), nitrofurantoin, and ertapenem. She has no fever, no costovertebral angle tenderness, and blood cultures from a prior episode of pyelonephritis 2 months ago were negative. The fellow considers prescribing fosfomycin trometamol 3 g oral single dose and asks the attending to review the appropriateness of this choice and its pharmacological limitations. Which of the following most accurately characterizes fosfomycin's clinical role, evidence base, and pharmacological limitations for this patient?
A) Fosfomycin trometamol 3 g single dose is inappropriate for ESBL-producing E. coli because ESBL enzymes co-transfer a fosfomycin-inactivating kinase (FosA3) on the same IncF plasmid in virtually all ESBL E. coli strains; in vitro susceptibility is therefore always a false positive reflecting enzyme expression suppression at the testing inoculum, and nitrofurantoin is the only reliably active non-carbapenem oral agent for ESBL cystitis
B) Fosfomycin is appropriate here but requires a 7-day course rather than a single dose; single-dose fosfomycin achieves therapeutic urine concentrations only for 24-48 hours and produces significantly lower cure rates than 7-day nitrofurantoin for ESBL cystitis in all published randomized trials; IDSA guidelines specifically contraindicate single-dose fosfomycin for ESBL-producing organisms because of inadequate duration of antibiotic exposure
C) Fosfomycin trometamol 3 g single dose is appropriate for this presentation but cannot be used if the patient develops pyelonephritis or bacteremia; fosfomycin's mechanism — inhibition of MurA (UDP-N-acetylglucosamine enolpyruvyl transferase), the first committed step in peptidoglycan synthesis — is not affected by ESBL enzymes because fosfomycin is not a beta-lactam; oral fosfomycin achieves adequate urine concentrations for uncomplicated cystitis, and the evidence supports its use as a guideline-endorsed first-line option for ESBL cystitis
D) Fosfomycin trometamol single dose is appropriate for this uncomplicated ESBL-producing E. coli cystitis; fosfomycin inhibits MurA and achieves high urinary concentrations after oral dosing, making it suitable for uncomplicated lower UTI; its limitations include: oral formulations are not suitable for systemic infections because serum concentrations after single oral dosing are inadequate for bacteremia treatment, some ESBL-producing E. coli carry co-transferred FosA3 resistance that can reduce susceptibility, and parenteral fosfomycin (not the oral trometamol formulation) is required for serious systemic infections in settings where it is available
E) Fosfomycin is contraindicated in patients with prior bacteremia from any source within the preceding 6 months because bacteremic episodes induce fosfomycin tolerance through upregulation of the glpT (glycerol-3-phosphate transporter) gene in circulating E. coli; the patient's bacteremia 2 months ago has produced persistent fosfomycin-tolerant E. coli gut colonization that renders oral fosfomycin ineffective for the current episode regardless of the MIC result
ANSWER: D
Rationale:
Option D is correct. Fosfomycin trometamol 3 g single oral dose is a guideline-endorsed option for uncomplicated ESBL-producing E. coli lower urinary tract infection (cystitis). Fosfomycin inhibits MurA (UDP-N-acetylglucosamine enolpyruvyl transferase), the enzyme catalyzing the first committed step in bacterial peptidoglycan synthesis — this mechanism is entirely independent of beta-lactamase activity, and ESBL enzymes do not affect fosfomycin. The oral trometamol formulation achieves high urinary concentrations far exceeding the MIC for susceptible organisms after a single 3 g dose, with urinary concentrations remaining therapeutic for 24-48 hours, which is sufficient for uncomplicated cystitis. IDSA and ESCMID guidelines specifically include fosfomycin as a first-line option for uncomplicated ESBL cystitis. The key limitations that make Option D the most complete and accurate answer are: (1) oral fosfomycin trometamol is a urinary-concentrated formulation not suitable for systemic infections — serum concentrations are inadequate for bacteremia treatment; (2) intravenous fosfomycin (a different formulation available in Europe and some other countries, not approved in the US for systemic use) is required for serious systemic infections; and (3) co-transferred FosA3 (and related FosA variants) on ESBL-carrying plasmids can inactivate fosfomycin and reduce susceptibility in some E. coli strains, though this is not universal and susceptibility testing should guide therapy.
Option A: Option A is incorrect because FosA3 co-transfer is not present in virtually all ESBL E. coli — prevalence varies by geographic region and plasmid type, and many ESBL E. coli strains retain fosfomycin susceptibility; in vitro susceptibility testing is clinically actionable when fosfomycin MIC is confirmed susceptible.
Option B: Option B is incorrect because single-dose fosfomycin trometamol 3 g is the standard approved regimen for uncomplicated cystitis; multiple randomized trials and IDSA guidelines support single-dose therapy for uncomplicated lower UTI, and 7-day courses are not specifically recommended for ESBL cystitis over single-dose.
Option C: Option C is incorrect because while its pharmacological explanation is sound, it fails to identify the FosA3 co-transfer limitation and the critical distinction between oral trometamol (urinary use only) and parenteral fosfomycin formulations needed for systemic infections; Option D is the more complete and accurate answer because it explicitly addresses both of these clinically important limitations that the clinician and pharmacist must know.
Option E: Option E is incorrect because prior bacteremia does not induce fosfomycin tolerance through glpT upregulation in the way described; the glpT transporter is fosfomycin's uptake mechanism and its downregulation (not upregulation) confers resistance, but prior bacteremia does not produce persistent transporter upregulation or fosfomycin tolerance in colonizing organisms.
11. A 55-year-old man is admitted to the medical ICU with healthcare-associated pneumonia and septic shock. He is started empirically on vancomycin plus piperacillin-tazobactam plus azithromycin. On day 3, sputum and blood cultures return: Streptococcus pneumoniae susceptible to penicillin G (MIC 0.06 mg/L), ceftriaxone, and azithromycin. The antibiotic stewardship team recommends de-escalating to ceftriaxone monotherapy. The fellow asks whether de-escalation is safe given the severity of the initial presentation and what the pharmacological rationale is for de-escalation beyond cost and side effect reduction. Which of the following best characterizes the pharmacological rationale for antibiotic de-escalation in this patient?
A) De-escalation is unsafe in septic shock survivors because the initial broad-spectrum regimen produced clinical stabilization through synergistic coverage of both the confirmed pathogen and undetected co-pathogens that culture methods miss; switching to narrow-spectrum therapy removes the synergistic component and risks clinical deterioration from undetected organisms that the targeted narrow-spectrum agent does not cover
B) De-escalation to ceftriaxone is pharmacokinetically inferior to continuation of piperacillin-tazobactam because ceftriaxone's time-dependent killing requires continuous IV infusion to maintain fT>MIC above 100% for S. pneumoniae; piperacillin-tazobactam's broader spectrum provides a pharmacokinetic buffer against intermittent dosing failures, making it the pharmacologically superior choice for continued therapy even after pathogen identification
C) De-escalation from broad-spectrum empiric therapy to targeted narrow-spectrum therapy once culture results confirm the causative pathogen and its susceptibilities reduces collateral antibiotic pressure on the patient's commensal microbiome; continued broad-spectrum therapy unnecessarily amplifies resistant subpopulations in the gut, respiratory, and skin microbiomes that serve as resistance gene reservoirs for the patient and their contacts, while narrow-spectrum therapy achieves equivalent pathogen-specific efficacy with substantially less ecological disruption
D) De-escalation is appropriate only if the patient achieves clinical cure criteria (afebrile for 48 hours, normalizing inflammatory markers, and negative repeat cultures) before switching; in septic shock survivors who remain on vasopressors at day 3, de-escalation is contraindicated regardless of culture results because the physiological stress of critical illness impairs absorption and distribution of narrow-spectrum agents through mechanisms that broad-spectrum agents are specifically formulated to overcome
E) De-escalation is a pharmacoeconomic intervention only; the clinical and microbiological outcomes of broad-spectrum continuation versus narrow-spectrum de-escalation are identical for susceptible pathogens because antibiotic spectrum does not affect the patient's own infection outcome — the rationale for de-escalation is exclusively hospital cost reduction and reduction of individual drug adverse effects, with no impact on resistance ecology at the patient or population level
ANSWER: C
Rationale:
Option C is correct. Antibiotic de-escalation — transitioning from broad-spectrum empiric therapy to targeted narrow-spectrum therapy once culture results and susceptibilities are confirmed — is a cornerstone antibiotic stewardship intervention supported by both clinical outcomes data and a strong pharmacological rationale. The pharmacological rationale beyond cost and adverse effects is ecological: every day of broad-spectrum antibiotic therapy maintains selection pressure on the entire microbial community colonizing the patient — gut (the largest bacterial reservoir in the body), respiratory tract, skin, and urinary tract. Broad-spectrum agents with activity against a wide range of organisms kill or suppress susceptible commensals, selectively amplifying resistant organisms already present in the microbiome. These resistant subpopulations carry resistance genes on mobile elements that can subsequently transfer to pathogens infecting this patient or be shed into the environment and transmitted to contacts. Narrowing to ceftriaxone for confirmed penicillin-susceptible S. pneumoniae infection maintains full efficacy against the pathogen while dramatically reducing collateral pressure on commensal flora that does not need to be affected. Multiple studies have demonstrated that de-escalation does not worsen clinical outcomes for confirmed pathogen infections and may improve outcomes by reducing C. difficile infection risk, drug adverse effects, and nosocomial superinfection with resistant organisms.
Option A: Option A is incorrect because de-escalation to a fully active narrow-spectrum agent does not remove synergistic coverage that protects against occult co-pathogens; penicillin-susceptible S. pneumoniae pneumonia is a clearly defined infection where ceftriaxone monotherapy is guideline-endorsed as definitive therapy, and hypothetical undetected co-pathogens are addressed by clinical monitoring rather than mandatory empiric broad-spectrum continuation.
Option B: Option B is incorrect because ceftriaxone administered every 24 hours achieves adequate fT>MIC for penicillin-susceptible S. pneumoniae given the very low MIC of 0.06 mg/L; ceftriaxone does not require continuous infusion for susceptible pneumococcal infections, and the pharmacokinetic buffer argument for piperacillin-tazobactam is not pharmacologically supported.
Option D: Option D is incorrect because de-escalation is not contraindicated in patients on vasopressors at day 3 when culture results confirm a susceptible organism and IV therapy is continued; the criterion for de-escalation is pathogen identification and susceptibility confirmation, not achievement of all clinical cure milestones; critical illness physiology does not impair IV antibiotic distribution of ceftriaxone in the way described.
Option E: Option E is incorrect because the pharmacological rationale for de-escalation is not exclusively pharmacoeconomic — the ecological impact on the patient's microbiome and the downstream resistance consequences for the patient and their contacts are established pharmacological and epidemiological rationales that are explicitly recognized in IDSA stewardship guidelines as primary justifications for de-escalation practice.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.